NL-OMON46152已完成不适用
Ablative tReatment of inoperable REnal cell carcinoma using STereotactic body Radiotherapy - ARREST
niversitair Medisch Centrum Utrecht0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Inoperability, or when a patient refuses surgery (i.e. not eligible for (partial-) nephrectomy or RFA);
- •- Kidney function allows for intervention, as evaluated by treating urologist (taking into account eGFR and renogram);
- •- Age * 18 years;
- •- Written informed consent;
- •- Diagnosis of RCC confirmed by pathology (in case determined after informed consent, patients who are not eligible anymore (no RCC) will be excluded).
排除标准
- •- Evidence of metastatic disease;
- •- Exclusion criteria for contrast enhanced MRI scan, according to the protocol of the department of Radiology, UMC Utrecht;
- •- Patients with one functioning kidney;
- •- Prior renal surgery (partial nephrectomy);
- •- Prior radiotherapy on upper abdomen;
- •- Unsafe to have fiducial marker implantation: i.e. anticoagulant agents use other than acetylsalicyl acid, which cannot be safely stopped/bridged for implantation;
- •- WHO * 3;
- •- Chemotherapy < 3 weeks before treatment;
- •- Targeted therapy (sunitinib etc) * 7 days before treatment.
研究者
相似试验
进行中（未招募）
1 期
Treatment of metastatic renal cell carcinoma by dendritic cells vaccination.Metatastic renal cell carcinomaEUCTR2011-004391-11-CZMasaryk University30
招募中
Unknown
ablation therapy for small renal cell carcinoma -cryoablation vs radiofrequency ablationrenal cancerJPRN-UMIN000052117Kochi University, Kochi Medical School40
进行中（未招募）
不适用
Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatique et intratumorale des molécules impliquées dans la voie VHL/HIF/VEGF. - S-TRACCarcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvanteMedDRA version: 9.1Level: LLTClassification code 10001326Term: Adrenal carcinomaMedDRA version: 9.1Level: LLTClassification code 10001327Term: Adrenal carcinoma NOSMedDRA version: 9.1Level: LLTClassification code 10038395Term: Renal carcinomaMedDRA version: 9.1Level: LLTClassification code 10038396Term: Renal carcinoma recurrentMedDRA version: 9.1Level: LLTClassification code 10038397Term: Renal carcinoma stage IMedDRA version: 9.1Level: LLTClassification code 10038398Term: Renal carcinoma stage IIMedDRA version: 9.1Level: LLTClassification code 10038399Term: Renal carcinoma stage IIIMedDRA version: 9.1Level: LLTClassification code 10038400Term: Renal carcinoma stage IVMedDRA version: 9.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaMedDRA version: 9.1Level: PTClassification code 10001326Term: Adrenal carcinomaEUCTR2007-005648-25-FRC.H.U. de RENNES
进行中（未招募）
1 期
A study of axitinib compared to placebo in the treatment of patients with renal cell carcinoma (kidney cancer)Renal Cell CarcinomaEUCTR2013-003905-24-ESSFJ Pharma Ltd. II592
已完成
不适用
Radiofrequency ablation for renal cell carcinoma using a switchin controllerrenal cell carcinomaJPRN-UMIN000002506Department of Radiology, Mie University Hospital33